ANGPTL4 oligonucleotides influencing the regulation of the fatty acid metabolism

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 12024708
SERIAL NO

17293356

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

An ANGPTL4 inhibitor consisting of an oligonucleotide has 12 to 22 nucleotides. At least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of human and/or mouse ANGPTL4 and inhibits the expression of ANGPTL4. Also disclosed herein is a pharmaceutical composition of the ANGPTL4 inhibitor and a pharmaceutically acceptable carrier, excipient, diluent, or a combination thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
LIPIGON PHARMACEUTICALS ABTVISTEVÄGEN 48C UMEÅ 90736

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Jaschinski, Frank Marburg, DE 27 179
Michel, Sven Marburg, DE 13 3
Sadewasser, Anne Marburg, DE 4 2

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jan 2, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 2, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 2, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00